Daniel Reker1,2,3,4, Steven M Blum1,5,6,7, Peter Wade1, Christoph Steiger1,3,4, Giovanni Traverso8,9,10,11. 1. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. 2. Department of Biomedical Engineering , Duke University , Durham, North Carolina, 27708, USA. 3. Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA. 4. MIT-IBM Watson AI Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. 5. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA. 6. Department of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA. 7. Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, 02114, USA. 8. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. cgt20@mit.edu. 9. Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, 02115, USA. cgt20@mit.edu. 10. MIT-IBM Watson AI Lab, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. cgt20@mit.edu. 11. Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, 02139, USA. cgt20@mit.edu.
Abstract
PURPOSE: A multitude of different versions of the same medication with different inactive ingredients are currently available. It has not been quantified how this has evolved historically. Furthermore, it is unknown whether healthcare professionals consider the inactive ingredient portion when prescribing medications to patients. METHODS: We used data mining to track the number of available formulations for the same medication over time and correlate the number of available versions in 2019 to the number of manufacturers, the years since first approval, and the number of prescriptions. A focused survey among healthcare professionals was conducted to query their consideration of the inactive ingredient portion of a medication when writing prescriptions. RESULTS: The number of available versions of a single medication have dramatically increased in the last 40 years. The number of available, different versions of medications are largely determined by the number of manufacturers producing this medication. Healthcare providers commonly do not consider the inactive ingredient portion when prescribing a medication. CONCLUSIONS: A multitude of available versions of the same medications provides a potentially under-recognized opportunity to prescribe the most suitable formulation to a patient as a step towards personalized medicine and mitigate potential adverse events from inactive ingredients.
PURPOSE: A multitude of different versions of the same medication with different inactive ingredients are currently available. It has not been quantified how this has evolved historically. Furthermore, it is unknown whether healthcare professionals consider the inactive ingredient portion when prescribing medications to patients. METHODS: We used data mining to track the number of available formulations for the same medication over time and correlate the number of available versions in 2019 to the number of manufacturers, the years since first approval, and the number of prescriptions. A focused survey among healthcare professionals was conducted to query their consideration of the inactive ingredient portion of a medication when writing prescriptions. RESULTS: The number of available versions of a single medication have dramatically increased in the last 40 years. The number of available, different versions of medications are largely determined by the number of manufacturers producing this medication. Healthcare providers commonly do not consider the inactive ingredient portion when prescribing a medication. CONCLUSIONS: A multitude of available versions of the same medications provides a potentially under-recognized opportunity to prescribe the most suitable formulation to a patient as a step towards personalized medicine and mitigate potential adverse events from inactive ingredients.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Joshua Pottel; Duncan Armstrong; Ling Zou; Alexander Fekete; Xi-Ping Huang; Hayarpi Torosyan; Dallas Bednarczyk; Steven Whitebread; Barun Bhhatarai; Guiqing Liang; Hong Jin; S Nassir Ghaemi; Samuel Slocum; Katalin V Lukacs; John J Irwin; Ellen L Berg; Kathleen M Giacomini; Bryan L Roth; Brian K Shoichet; Laszlo Urban Journal: Science Date: 2020-07-24 Impact factor: 47.728
Authors: Daniel Reker; Steven M Blum; Christoph Steiger; Kevin E Anger; Jamie M Sommer; John Fanikos; Giovanni Traverso Journal: Sci Transl Med Date: 2019-03-13 Impact factor: 17.956
Authors: David S Wishart; Yannick D Feunang; An C Guo; Elvis J Lo; Ana Marcu; Jason R Grant; Tanvir Sajed; Daniel Johnson; Carin Li; Zinat Sayeeda; Nazanin Assempour; Ithayavani Iynkkaran; Yifeng Liu; Adam Maciejewski; Nicola Gale; Alex Wilson; Lucy Chin; Ryan Cummings; Diana Le; Allison Pon; Craig Knox; Michael Wilson Journal: Nucleic Acids Res Date: 2018-01-04 Impact factor: 16.971